

Exhibit 4

Subject: RE: [EXTERNAL] RE: FDA Receipt of FOI Request Control # 2021-7545

Date: Friday, May 13, 2022 at 4:15:09 PM Pacific Daylight Time

From: S&G Information Request Staff

To: Sly, Elizabeth, S&G Information Request Staff

Dear Ms. Sly,

Our request is limited to the original emergency use authorization of the Pfizer/Biotech vaccine.

Thank you,

Annalise Beube, Law Clerk

Siri | Glimstad

700 S Flower Street

Suite 1000

Los Angeles, CA 90017

Main: 212-532-1091

Facsimile: 646-417-5967

www.sirillp.com

This email may contain material that is confidential, privileged and/or attorney work product for the sole use of the intended recipient. Any review, reliance or distribution by others or forwarding without express permission is strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies.

From: Sly, Elizabeth <Elizabeth.Sly@fda.hhs.gov>

Sent: Tuesday, March 22, 2022 11:32 AM

To: S&G Information Request Staff <foia@sirillp.com>

Subject: RE: [EXTERNAL] RE: FDA Receipt of FOI Request Control # 2021-7545

Dear Ms. Beube,

In order to provide you with the most accurate estimate, can you please provide me with some additional clarification?

The original wording of your request is for “All documents related to dose determination for the Pfizer COVID-19 vaccine, including documents reflecting process(es) used to determine dose and the data used to support the process(es). These documents may include, but should not be limited to, communications, meeting recordings, transcripts, or minutes wherein dose determination was discussed and/or decided” and your request was received by CBER on November 3, 2021.

Is the scope of your request limited to the original approval of COMIRNATY (approval August 23, 2021) regarding individuals 16 years of age and older?

Sincerely,

Elizabeth Sly, M.S.

Microbiologist

Phone: 240.402.8001

Email: Elizabeth.Sly@fda.hhs.gov

Access Litigation and Freedom of Information Branch (ALFOIB)
Division of Disclosure and Oversight Management (DDOM)
Office of Communication Outreach and Development (OCOD)
Center for Biologics Evaluation and Research (CBER)
U.S. Food and Drug Administration (FDA)

From: FDA FOIA <FDAFOIA@fda.hhs.gov>
Sent: Monday, March 21, 2022 8:05 AM
To: S&G Information Request Staff <foia@sirillp.com>; Sly, Elizabeth <Elizabeth.Sly@fda.hhs.gov>
Subject: RE: [EXTERNAL] RE: FDA Receipt of FOI Request Control # 2021-7545

Annalise,

Your request is open to CBER, I have copied Elizabeth so that she can provide an estimate of response.

Regards,

Katherine

From: S&G Information Request Staff <foia@sirillp.com>
Sent: Friday, March 18, 2022 6:28 PM
To: FDA_FOI@fda.gov
Cc: FDA FOIA <FDAFOIA@fda.hhs.gov>; S&G Information Request Staff <foia@sirillp.com>
Subject: [EXTERNAL] RE: FDA Receipt of FOI Request Control # 2021-7545

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Sir or Madam,

Could you please provide an estimated date of completion?

Annalise Beube, Law Clerk

Siri | Glimstad

700 S Flower Street
Suite 1000
Los Angeles, CA 90017
Main: 212-532-1091
Facsimile: 646-417-5967
www.sirillp.com

This email may contain material that is confidential, privileged and/or attorney work product for the sole use of the intended recipient. Any review, reliance or distribution by others or forwarding without express permission is strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies.

From: FDA_FOI@fda.gov <FDA_FOI@fda.gov>
Sent: Wednesday, November 3, 2021 4:47 AM
To: S&G Information Request Staff <foia@sirillp.com>
Cc: FDAFOIA@fda.hhs.gov
Subject: FDA Receipt of FOI Request Control # 2021-7545

Control number: 2021-7545

Please find the attached acknowledgement regarding your FOIA request.

Note: Do NOT reply directly to this E-mail